NCT01950364 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 20
- units
- Participants
- groups
- description
- Brentuximab vedotin 1.8 mg/kg, injection, intravenously, every 3 weeks on Day 1 of each 21-day treatment cycle up to a maximum of 16 brentuximab vedotin doses.
- id
- BG000
- title
- Brentuximab Vedotin
- description
- Brentuximab vedotin 1.8 mg/kg, injection, intravenously, every 3 weeks on Day 1 of each 21-day treatment cycle up to a maximum of 16 brentuximab vedotin doses and rifampicin, 600 mg, capsules, orally, once daily from Day 1 of treatment Cycle 0 through Day 21 of treatment cycle 3.
- id
- BG001
- title
- Brentuximab Vedotin + Rifampicin
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 12.15
- value
- 42.3
- group Id
- BG001
- spread
- 9.13
- value
- 40.1
- group Id
- BG002
- spread
- 10.52
- value
- 41.2
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 9
- title
- Female
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 11
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 20
- title
- White
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 20
- title
- Not Hispanic or Latino
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 9
- title
- Spain
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- title
- Belgium
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 8
- title
- Lithuania
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 17.056
- value
- 71.11
- group Id
- BG001
- spread
- 24.213
- value
- 76.84
- group Id
- BG002
- spread
- 20.595
- value
- 73.98
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Weight
- unit Of Measure
- kilogram (kg)
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 3.80
- value
- 169.9
- group Id
- BG001
- spread
- 6.45
- value
- 169.7
- group Id
- BG002
- spread
- 5.15
- value
- 169.8
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Height
- unit Of Measure
- centimeter (cm)
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 9
- title
- 0
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 10
- title
- 1
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- 2
- description
- ECOG performance status is used to assess how the disease affects the daily living abilities of the participant. It ranges on the scale from 0-5 (0= normal activity; 1= symptoms but ambulatory; 2= in bed for less than (\<) 50 percent (%) of the time; 3= in bed for greater than (\>) 50% of the time; 4= 100% bedridden; 5= dead.
- param Type
- NUMBER
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 20
- title
- Hodgkin lymphoma
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- sALCL
- param Type
- NUMBER
- title
- Disease Type
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 31.23
- value
- 34.7
- group Id
- BG001
- spread
- 46.96
- value
- 61.9
- group Id
- BG002
- spread
- 41.25
- value
- 48.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Months from Initial Diagnosis to First Dose
- unit Of Measure
- months
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- I
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 8
- title
- II
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- III
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 10
- title
- IV
- description
- Ann Arbor staging is staging system for lymphomas. The stage is determined by location of tumor. Stage I (located in a single region, usually 1 lymph node and surrounding area), Stage II (located in 2 separate regions, an affected lymph node or organ and a second affected area, and both affected areas are confined to 1 side of diaphragm), Stage III (spread to both sides of diaphragm, including organ/area near lymph nodes/spleen), Stage IV (diffuse or disseminated involvement of 1 or more extra lymphatic organs, including any involvement of liver, bone marrow or nodular involvement of lungs).
- param Type
- NUMBER
- title
- Ann Arbor Stage
- unit Of Measure
- participants
- population Description
- Safety population included all participants who received at least 1 dose of study drug.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 20
- units
- Participants
- groups
- description
- Brentuximab vedotin 1.8 mg/kg, injection, intravenously, every 3 weeks on Day 1 of each 21-day treatment cycle up to a maximum of 16 brentuximab vedotin doses.
- id
- BG000
- title
- Brentuximab Vedotin
- description
- Brentuximab vedotin 1.8 mg/kg, injection, intravenously, every 3 weeks on Day 1 of each 21-day treatment cycle up to a maximum of 16 brentuximab vedotin doses and rifampicin, 600 mg, capsules, orally, once daily from Day 1 of treatment Cycle 0 through Day 21 of treatment cycle 3.
- id
- BG001
- title
- Brentuximab Vedotin + Rifampicin
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 12.15
- value
- 42.3
- group Id
- BG001
- spread
- 9.13
- value
- 40.1
- group Id
- BG002
- spread
- 10.52
- value
- 41.2
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 9
- title
- Female
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 11
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 20
- title
- White
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 20
- title
- Not Hispanic or Latino
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 9
- title
- Spain
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- title
- Belgium
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 8
- title
- Lithuania
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 17.056
- value
- 71.11
- group Id
- BG001
- spread
- 24.213
- value
- 76.84
- group Id
- BG002
- spread
- 20.595
- value
- 73.98
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Weight
- unit Of Measure
- kilogram (kg)
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 3.80
- value
- 169.9
- group Id
- BG001
- spread
- 6.45
- value
- 169.7
- group Id
- BG002
- spread
- 5.15
- value
- 169.8
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Height
- unit Of Measure
- centimeter (cm)
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 9
- title
- 0
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 10
- title
- 1
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- 2
- description
- ECOG performance status is used to assess how the disease affects the daily living abilities of the participant. It ranges on the scale from 0-5 (0= normal activity; 1= symptoms but ambulatory; 2= in bed for less than (\<) 50 percent (%) of the time; 3= in bed for greater than (\>) 50% of the time; 4= 100% bedridden; 5= dead.
- param Type
- NUMBER
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 20
- title
- Hodgkin lymphoma
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- sALCL
- param Type
- NUMBER
- title
- Disease Type
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 31.23
- value
- 34.7
- group Id
- BG001
- spread
- 46.96
- value
- 61.9
- group Id
- BG002
- spread
- 41.25
- value
- 48.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Months from Initial Diagnosis to First Dose
- unit Of Measure
- months
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- I
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 8
- title
- II
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- III
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 10
- title
- IV
- description
- Ann Arbor staging is staging system for lymphomas. The stage is determined by location of tumor. Stage I (located in a single region, usually 1 lymph node and surrounding area), Stage II (located in 2 separate regions, an affected lymph node or organ and a second affected area, and both affected areas are confined to 1 side of diaphragm), Stage III (spread to both sides of diaphragm, including organ/area near lymph nodes/spleen), Stage IV (diffuse or disseminated involvement of 1 or more extra lymphatic organs, including any involvement of liver, bone marrow or nodular involvement of lungs).
- param Type
- NUMBER
- title
- Ann Arbor Stage
- unit Of Measure
- participants
- population Description
- Safety population included all participants who received at least 1 dose of study drug.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle